PODCAST

MAP - Market Access Podcast

Dr. Stefan Walzer

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?Digital Health Care is already fully utilized in the US, isn’t it?
Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might we expect with the Biden administration? And what are the next steps to take? In order to make it even more practical, Anna Forsythe the Managing Partner at Purple Squirrel Economics and expert in global product commercialization and strategic drug development, has joined the discussion in the second half of the discussion. Don't miss these insights as well. The US market is for sure very interesting for digital healthcare products. This podcast episode will help you to get an idea of your next steps to enter this attractive market.  Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:  MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/ (https://marketaccess-pricingstrategy.de/en/map-podcast/) Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559 (https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559)    Spotify 🎧 https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819 (https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819)   Amazon music 📶 https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast (https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast)   MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 (https://lnkd.in/dDCTND2)  #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #usa #diga #digital
Apr 1 2022
1 hr 1 min
Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and his experts from Italy Prof. Dr. Stefano Capri and Dr. Entela Xoxi.  Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:  MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/ (https://marketaccess-pricingstrategy.de/en/map-podcast/) Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559 (https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559)    Spotify 🎧 https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819 (https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819)   Amazon music 📶 https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast (https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast)   MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 (https://lnkd.in/dDCTND2)  #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #italy
Mar 15 2022
28 mins
What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system. The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also the similarities between Germany and the Austrian system. On top, the joint EU HTA approach will also be included in a scenario analysis in terms of implementation. Listen into this breakthrough discussions with a span between Austria, Germany the EU. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:  MArS🎙 https://marketaccess-pricingstrategy.de/en/map-podcast/ (https://marketaccess-pricingstrategy.de/en/map-podcast/) Apple 🍏 https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559 (https://podcasts.apple.com/de/podcast/map-market-access-podcast/id1583167559)    Spotify 🎧 https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819 (https://open.spotify.com/show/7E8ZmM8oVVMCO6ewp4djiu?si=287017e1b3d54819)   Amazon music 📶 https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast (https://music.amazon.com/podcasts/f16a1357-0bc6-43fa-9516-dc9b883dc883/map---market-access-podcast)   MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 (https://lnkd.in/dDCTND2)  #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #austria
Mar 1 2022
30 mins
The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?How do innovations reach patients in German hospitals, Dr. Sebastian Casu?How does hospital funding work in Germany, Willi Wöllner?Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?Dr. Mathias Flume - AMNOG will change in 2022, but how?